CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Immune response following intraocular delivery of recombinant viral vectors

Bennett, J·2003·Gene Therapy
DOI 10.1038/sj.gt.3302030
Open this paper in CoChat — free account

Abstract

There has been significant progress in the last few years in demonstrating the utility of recombinant viral vectors in treating a variety of ocular diseases. The field has moved beyond 'proof-of-principle' and, in fact, has entered the phase where some of these vectors/paradigms are being or soon will be evaluated in human clinical trials. For this reason and also, to increase the understanding of immunological effects of transgenes/viral vectors on the eye, it is important to summarize what is known about these effects. Here, the biology of and immune responses to intraocular injection of three different recombinant viral vectors - adenovirus, adeno-associated virus (AAV), and lentivirus - are summarized. Perhaps, in part because of the unique immunological environment of the eye, the immunological effects of these viruses appear to be fairly benign. Nevertheless, a significant cell-mediated immune response can develop after intraocular administration of adenovirus. The magnitude of this response is affected by the nature of the intraocular compartment to which this virus is administered. Neither AAV nor lentivirus, however, elicit a cell-mediated response and are thus promising vectors for treatment of chronic ocular (retinal) diseases.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.gt.3302030

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 53

  1. Chowers I et al. Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001; 85: 991–995.
  2. Liu X et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999; 69: 385–395. · DOI
  3. Sun N, Cassell M, Perlman S . Anterograde, transneuronal transport of Herpes simplex virus type 1 strain H129 in the murine visual system. J Virol 1996; 70: 5405–5413. · DOI
  4. Haeseleer F, Imanashi Y, Saperstein D, Palczewski K . Gene transfer mediated by recombinant baculovirus into mouse eye. Invest Ophthalmol Vis Sci 2001; 42: 3294–3300.
  5. Bennett J et al. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994; 35: 2535–2542.
  6. Li T et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci 1994; 35: 2543–2549.
  7. Bennett J, Anand V . Recombinant adenovirus and ocular gene therapy. International Retinitis Pigmentosa Association, 1999, http://www.irpa.org/sci-news/topbenne.htm
  8. Budenz D, Bennett J, Alonso L, Maguire A . In vivo gene transfer into murine trabecular meshwork and corneal endothelial cells. Invest Ophthalmol Vis Sci 1995; 36: 2211–2215.
  9. Larkin DF et al. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996; 61: 363–370. · DOI
  10. Fehervari Z et al. Gene transfer to ex vivo stored corneas. Cornea 1997; 16: 459–464. · DOI
  11. Peterson WM et al. Enhanced survival of photoreceptors in P23H mutant rhodopsin transgenic rats by adeno-associated virus (AAV)-mediated delivery of neurotrophic genes. Invest Ophthalmol Vis Sci 1998; 39: S1117.
  12. McGee LH et al. Rescue of photoreceptor degeneration in S334ter(4) mutant rhodopsin transgenic rats by adeno-associated virus (AAV)-mediated delivery of basic fibroblast growth factor. Invest Ophthalmol Vis Sci 1999; 40: S936.
  13. Ali R et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 2000; 25: 306–310. · DOI
  14. Lau D et al. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Invest Ophthalmol Vis Sci 2000; 41: 3622–3633.
  15. Liang F-Q et al. Long-term protection of retinal structure but not function using rAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 2001; 4: 461–472. · DOI
  16. Sarra G-M et al. Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. Hum Mol Genet 2001; 10: 2353–2361. · DOI
  17. Auricchio A et al. Inhibition of retinal neovascularization by intraocular viral mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490–494. · DOI
  18. McGee SL, Abel H, Hauswirth W, Flannery J . Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol Ther 2001; 4: 622–629. · DOI
  19. Jomary C et al. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Therapy 1997; 4: 683–690. · DOI
  20. Ali RR et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996; 5: 591–594. · DOI
  21. Flannery J et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 6916–6921. · DOI
  22. Bennett J, Duan D, Engelhardt J, Maguire AM . Real-time non-invasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci 1997; 38: 2857–2863.
  23. Ho T et al. Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J Gene Med 2002; 4: 613–621. · DOI
  24. Bennett J, Anand V, Acland GM, Maguire AM . Cross-species comparison of in vivo reporter gene expression after rAAV-mediated retinal transduction. Methods Enzymol 2000; 316: 777–789. · DOI
  25. Auricchio A et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001; 10: 3075–3081. · DOI
  26. Rabinowitz J et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791–801. · DOI · Paper page
  27. Streilein J . Immune regulation and the eye: a dangerous compromise. FASEB J 1987; 1: 199–208. · DOI
  28. Kosiewicz M, Alard P, Streilein J . Alterations in cytokine production following intraocular injection of soluble protein antigen: impairment in IFN-g and induction of TGF-b and IL-4 production. J Immunol 1998; 161: 5382–5390. · DOI
  29. D'Orazio T, Niederkorn J . The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response. Eur J Immunol 1998; 28: 1544–1553. · DOI
  30. Jiang LQ, Jorquera M, Streilein JW, Ishioka M . Unconventional rejection of neural retinal allografts implanted into the immunologically privileged site of the eye. Transplantation 1995; 59: 1201–1207. · DOI
  31. Wenkel H, Streilein JW . Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest Ophthalmol Vis Sci 1998; 39: 1823–1834.
  32. Wilbanks GA, Streilein JW . Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991; 146: 2610–2617. · DOI
  33. Wilson SE et al. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Exp Eye Res 1994; 59: 63–71. · DOI
  34. Khaw PT, Schultz GS, MacKay SL . Detection of transforming growth factor – alpha messenger RNA and protein in human corneal epithelial cells. Invest Ophthalmol Vis Sci 1992; 33: 3302–3306.
  35. Taylor AW, Streilein JW, Cousins SW . Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 1994; 153: 1080–1086. · DOI
  36. Griffith TS et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189. · DOI
  37. Shimada K . The complement component and their inactivators in the intraocular fluids of the guinea pig. Invest Ophthalmol Vis Sci 1970; 9: 307–315.
  38. Bora NS et al. Differential expression in the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993; 34: 3579–3584.
  39. Hoffman LM, Maguire AM, Bennett J . Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci 1997; 38: 2224–2233.
  40. Maguire AM et al. Adenovirus-mediated gene transfer to canine retinal photoreceptors: effects of inflammation. Invest Ophthalmol Vis Sci 1995; 36: S777.
  41. Judge TA et al. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996; 156: 2294–2299. · DOI
  42. Ali RR et al. Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina. Gene Therapy 1998; 5: 1561–1565. · DOI
  43. Di Polo A et al. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci USA 1998; 95: 3978–3983. · DOI
  44. Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223. · DOI · Paper page
  45. Anand V et al. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther 2002; 5: 125–132. · DOI · Paper page
  46. Bennett J, Pakola S, Zeng Y, Maguire AM . Humoral antibody response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space. Human Gene Ther 1996; 7: 1763–1769. · DOI
  47. Hurwitz M et al. Suicide gene therapy for treatment of retinoblastoma in a murine model. Human Gene Ther 1999; 10: 441–448. · DOI
  48. Rasmussen H et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029–2032.
  49. Blacklow NR et al. Epidemiology of adeno-associated virus infection in a nursery population. Am J Epidemiol 1968; 88: 368–378. · DOI
  50. Samulski RJ, Chang L-S, Shenk T . Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822–3828. · DOI
  51. Li X, D'Orazio L, Niederkorn J . Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Immunology 1996; 89: 34–40. · DOI
  52. Anand V, Maguire AM, Bennett J . High levels of transgene expression after readministration of adeno-associated virus to the subretinal space. Invest Ophthalmol Vis Sci 1999; 40: S592.
  53. Bennett J et al. Recombinant adeno-associated virus-mediated gene transfer to the monkey retina. Proc Natl Acad Sci USA 1999; 96: 9920–9925. · DOI

Cited by

Sorted by citations

See all 111

Metadata

Authors
Bennett, J.
Venue
Gene Therapy
Publisher
Springer Science and Business Media LLC
Published
2003-05-20
Volume
10
Issue
11
Pages
977-982
ISSN
  • 0969-7128
  • 1476-5462
DOI
10.1038/sj.gt.3302030
Cited by
111
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review